Intralesional measles, mumps, rubella (MMR) vaccine versus tuberculin purified protein derivative (PPD) in the treatment of palmoplantar and periungual warts: A randomized controlled trial
Phase 3
Completed
- Conditions
- warts , tuberculin purified protein derivative (PPD), measles, mumps, rubella (MMR) vaccine , intralesionalClearance of warts
- Registration Number
- TCTR20200604014
- Lead Sponsor
- Division of Dermatology, Department of medicine, Faculty of Medicine, Ramathibodi hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
At least one palmoplantar or periungual wart.
Personal history of MMR vaccine
Exclusion Criteria
History of topical treatment of target wart within 2 weeks or other treatment target warts within 4 weeks prior to our study
Have fever or other inflammation or infection in any part of body
Immunocompromised host, using immunosuppressive drugs, or current radiotherapy
Receiving immunoglobulin within 6 weeks
pregnant or lactating women
currently using anticoagulant drugs
Personal history of asthma, severe dermatitis, meningitis, TB, epilepsy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Complete remission of target wart lesion 6 months after final treatment Clinical evaluation by a blind evaluator
- Secondary Outcome Measures
Name Time Method Complete remission of distant wart lesion 6 months after final treatment Clinical evaluation by a blind evaluator,Treatment response by area changes of target wart Every visit Area of target wart/ Image J software,Treatment response by area changes of distant wart Every visit Area of target wart/ Image J software,Treatment response by clinical improvement of target wart Every visit Improvement percentages/ clinical assessment ,Treatment response by clinical improvement of distant wart Every visit Improvement percentages/ clinical assessment ,Characteristics of target wart First visit Dermoscope,Characteristics of distant wart First visit Dermoscope ,Pain score Every treatment session Visual analog scale ,Recurrence 6 months after final treatment The development of a wart in a treated area